HEMOSTEMIX INC (HEM.CA) Stock Fundamental Analysis

TSX-V:HEM • CA4236943060

0.08 CAD
-0.01 (-11.11%)
Last: Feb 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to HEM. HEM was compared to 24 industry peers in the Biotechnology industry. HEM has a bad profitability rating. Also its financial health evaluation is rather negative. HEM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • HEM had negative earnings in the past year.
  • In the past year HEM has reported a negative cash flow from operations.
  • HEM had negative earnings in each of the past 5 years.
  • HEM had a negative operating cash flow in each of the past 5 years.
HEM.CA Yearly Net Income VS EBIT VS OCF VS FCFHEM.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

  • The Return On Assets of HEM (-253.72%) is worse than 66.67% of its industry peers.
Industry RankSector Rank
ROA -253.72%
ROE N/A
ROIC N/A
ROA(3y)-728.69%
ROA(5y)-727.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HEM.CA Yearly ROA, ROE, ROICHEM.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

  • HEM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HEM.CA Yearly Profit, Operating, Gross MarginsHEM.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • HEM has more shares outstanding than it did 1 year ago.
  • HEM has more shares outstanding than it did 5 years ago.
  • HEM has a better debt/assets ratio than last year.
HEM.CA Yearly Shares OutstandingHEM.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HEM.CA Yearly Total Debt VS Total AssetsHEM.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

  • Based on the Altman-Z score of -76.46, we must say that HEM is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of HEM (-76.46) is worse than 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -76.46
ROIC/WACCN/A
WACCN/A
HEM.CA Yearly LT Debt VS Equity VS FCFHEM.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

2.3 Liquidity

  • A Current Ratio of 1.54 indicates that HEM should not have too much problems paying its short term obligations.
  • HEM has a better Current ratio (1.54) than 66.67% of its industry peers.
  • A Quick Ratio of 1.54 indicates that HEM should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.54, HEM is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.54
HEM.CA Yearly Current Assets VS Current LiabilitesHEM.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for HEM have decreased strongly by -36.36% in the last year.
EPS 1Y (TTM)-36.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HEM.CA Yearly EPS VS EstimatesHEM.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 -0.05 -0.1

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HEM. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HEM.CA Price Earnings VS Forward Price EarningsHEM.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HEM.CA Per share dataHEM.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0 -0.01 -0.01 -0.02 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for HEM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HEMOSTEMIX INC

TSX-V:HEM (2/12/2026, 7:00:00 PM)

0.08

-0.01 (-11.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-26
Earnings (Next)04-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners18.37%
Ins Owner ChangeN/A
Market Cap15.62M
Revenue(TTM)N/A
Net Income(TTM)-3.40M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -253.72%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-728.69%
ROA(5y)-727.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.54
Altman-Z -76.46
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-298.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-151.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-151.98%
OCF growth 3YN/A
OCF growth 5YN/A

HEMOSTEMIX INC / HEM.CA FAQ

What is the ChartMill fundamental rating of HEMOSTEMIX INC (HEM.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to HEM.CA.


What is the valuation status of HEMOSTEMIX INC (HEM.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to HEMOSTEMIX INC (HEM.CA). This can be considered as Overvalued.


How profitable is HEMOSTEMIX INC (HEM.CA) stock?

HEMOSTEMIX INC (HEM.CA) has a profitability rating of 0 / 10.


How financially healthy is HEMOSTEMIX INC?

The financial health rating of HEMOSTEMIX INC (HEM.CA) is 2 / 10.